- Please check and comment entries here.
Oral Magnesium for Hypertension
Oral magnesium therapy added to treatment regimens of patients with partially controlled hypertension holds promise as a way of safely achieving lower BP without increasing antihypertensive medications. Prescribing magnesium supplements to hypertensive but untreated patients may not lower BP unless the daily magnesium dose meets or exceeds 600 mg/day, which can be safely and economically accomplished, but magnesium doses below this level can achieve other cardiovascular risk factor improvements without the side effects of antihypertensive medications.
More than any other modifiable risk factor, hypertension is responsible for cardiovascular disease deaths both globally  and in the United States . Given the potential harms and costs of hypertension and the need for safe lowering of this important risk factor , we probed the large trove of research on oral magnesium therapy for hypertension and BP hoping to discern any prescription guidance.
Oral magnesium therapy for the treatment of hypertension has been well studied over the last 35 years but results are highly mixed. The trials differ not only in oral magnesium dose and form of magnesium but also in normotensive vs. hypertensive status at baseline as well as use or non-use of antihypertensive medications. Fourteen clinical trials have shown that oral magnesium therapy significantly lowers both systolic blood pressure (SBP) and diastolic blood pressure (DBP), whereas > twice that number of studies have shown no statistically significant lowering of either SBP, DBP, or both with oral magnesium therapy. Of six meta-analyses on this topic conducted to date , one shows no effect of oral magnesium on BP, one shows lowering of DBP but not SBP, four show that oral magnesium therapy lowers both SBP and DBP but only one of these suggests that the BP reductions are clinically relevant. Such results do not lend confidence in prescribing oral magnesium therapy to control or prevent high blood pressure. However, magnesium’s low cost, safety, positive research in cardiovascular risks  plus its partial beneficial BP results encourages this inclusive analytical categorization of all of these studies.
2. Effectively Prescribing Oral Magnesium Therapy for Hypertension
This categorization clearly shows that NT study subjects, both Controlled Hypertensives and Normotensive (i.e., those with an untreated healthy BP), will not show lower BP with oral magnesium therapy, even at high doses. However, several studies in these normotensive categories reported significant improvement in blood magnesium, lipoproteins, C-reactive protein, fasting glucose and insulin resistance, reversal of retinal vasospasm and increased sodium excretion, all of cardiovascular risk factor benefit. Oral magnesium therapy in NT patients, treated with antihypertensive medications or not, may not show improved BP readings, but these individuals may benefit from improved cardiovascular risk factors.
Among subjects who are hypertensive (≥140/90 mm Hg; MBP ≥ 106 mm Hg) at baseline, both low and high doses of oral magnesium therapy show significant decreases in both SBP and DBP only if the subjects are concurrently taking antihypertensive medications, i.e., partially or Uncontrolled Hypertensives. In the studies of Untreated Hypertensive subjects taking no antihypertensive medications, only the studies with Mg supplement doses >600 mg/day demonstrated statistically significant improvements in blood pressure by the criteria of this analysis. Subjects on lower magnesium doses showed other improvements in measures important to cardiovascular health such as serum magnesium, endothelial function and sodium excretion.
Magnesium-replete subjects, even those who are hypertensive, did not show a decrease in BP with oral magnesium therapy, even at doses as high as 972 mg/day . This finding indicates that a person can have adequate magnesium status and still have high BP. Other essential electrolytes besides magnesium can impact BP. For these patients, potassium could be low, especially when concurrent with a high sodium and/or low calcium intake.
The main limitation to this study is the lack of quantification of the BP changes, instead using the statistics and conclusions from each individual study, which varied widely. This study is not a precise meta-analysis and makes no attempt to fully quantify the impact of the categories derived from this analysis. This, rather, is the job of future meta-analyses, and we see this categorization as a preliminary study to guide future meta-analysis that may provide enhanced information about oral Mg therapy for BP while hopefully achieving lower heterogeneity than existing meta-analyses without losing precision. Nonetheless, this categorization of studies by hypertensive as well as medication status plus magnesium dose yields an informative framework for the prescription of oral magnesium therapy for high BP. It well accommodates large and small studies (n = 7–227 receiving magnesium therapy), short-term and long-term studies (2–26 weeks), 11 different forms of magnesium preparations (four inorganic and seven organic), parallel as well as crossover study designs, and placebo control or not (see Michon et al. , Sebekova et al. , Shafique et al. , Motoyama et al. , Cohen et al. , and Haga , which are studies not included in most meta-analyses due to no true placebo group).
Over 30 years ago, magnesium was shown to alter vascular constriction  and several studies have since shown that the physiology and cellular biochemistry of magnesium is important to the functionality of endothelial and smooth muscle cells and regulation of vascular tone . Decreased magnesium concentrations have been implicated in altered vascular reactivity, endothelial dysfunction, vascular inflammation, and structural remodeling . Low dietary magnesium has been associated with a higher risk of hypertension . In the United States, 67% of the population aged ≥51 years is low in dietary magnesium  and 55% of adults aged 19 to 50 years, 60% aged 51 to 70 years, and 78% aged >71 years do not consume their estimated average requirement for magnesium . Therefore, it is not surprising that prescribing oral magnesium therapy can lower a high BP. However, this categorized review of clinical trials shows that medication status, hypertensive status, and magnesium dose all must be considered in the use of this inexpensive, non-invasive, safe, readily available, “lifestyle” therapy to prevent and treat high BP as well as other conditions for which high BP is a risk factor. Pervasive low dietary magnesium status affects the health and health care systems of national and global populations . Chronic low dietary magnesium quite likely constitutes one of the “lifestyle” components in the high risk of cardiovascular disease of our time .
The entry is from 10.3390/nu13010195
- Lim, S.S.; Vos, T.; Flaxman, A.D.; Danaei, G.; Shibuya, K.; Adair-Rohani, H.; AlMazroa, M.A.; Amann, M.; Anderson, H.R.; Andrews, K.G.; et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2224–2260.
- Forouzanfar, M.H.; Liu, P.; Roth, G.A.; Ng, M.; Biryukov, S.; Marczak, L.; Alexander, L.; Estep, K.; Abate, K.H.; Akinyemiju, T.F.; et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA 2017, 317, 165–182.
- Danaei, G.; Ding, E.L.; Mozaffarian, D.; Taylor, B.; Rehm, J.; Murray, C.J.L.; Ezzati, M. The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors. PLoS Med. 2009, 6, e1000058.
- Wilt, T.J.; Kansagara, D.; Qaseem, A.; Clinical Guidelines Committee of the American College of Physicians. Hypertension Limbo: Balancing Benefits, Harms, and Patient Preferences Before We Lower the Bar on Blood Pressure. Ann. Intern. Med. 2018, 168, 369–370.
- Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E., Jr.; Collins, K.J.; Dennison Himmelfarb, C.; DePalma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018, 71, 1269–1324.
- Ioannidis, J.P.A. Diagnosis and Treatment of Hypertension in the 2017 ACC/AHA Guidelines and in the Real World. JAMA 2018, 319, 115.
- Muntner, P.; Carey, R.M.; Gidding, S.; Jones, D.W.; Taler, S.J.; Wright, J.T.; Whelton, P.K. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation 2018, 137, 109–118.
- Carey, R.M.; Whelton, P.K. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann. Intern. Med. 2018, 168, 351–358.
- Rosanoff, A.; Plesset, M.R. Oral magnesium supplements decrease high blood pressure (SBP > 155mmHg) in hypertensive subjects on anti-hypertensive medications: A targeted meta-analysis. Magnes. Res. 2013, 26, 93–99.
- Dibaba, D.T.; Xun, P.; Song, Y.; Rosanoff, A.; Shechter, M.; He, K. The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2017, 106, 921–929.
- Dickinson, H.O.; Nicolson, D.; Campbell, F.; Cook, J.V.; Beyer, F.R.; A Ford, G.; Mason, J. Magnesium supplementation for the management of primary hypertension in adults. Cochrane Database Syst. Rev. 2006, 3, CD004640.
- Jee, S.H.; Miller, E.R.; Guallar, E.; Singh, V.K.; Appel, L.J.; Klag, M.J. The effect of magnesium supplementation on blood pressure: A meta-analysis of randomized clinical trials. Am. J. Hypertens. 2002, 15, 691–696.
- Kass, L.S.; Weekes, J.; Carpenter, L.W. Effect of magnesium supplementation on blood pressure: A meta-analysis. Eur. J. Clin. Nutr. 2012, 66, 411–418.
- Zhang, X.; Li, Y.; Del Gobbo, L.C.; Rosanoff, A.; Wang, J.; Zhang, W.; Song, Y. Effects of Magnesium Supplementation on Blood Pressure. Hypertension 2016, 68, 324–333.
- Costello, R.B.; Rosanoff, A. Magnesium. In Present Knowledge in Nutrition, 11th ed.; Basic Nutrition and Metabolism; Marriott, B., Birt, D.F., Stalling, V., Yates, A., Eds.; ILSI-Academic Press: Washington, DC, USA, 2020; pp. 349–373.
- Rosique-Esteban, N.; Guasch-Ferré, M.; Hernandez-Alonso, P.; Salas-Salvadó, J. Dietary Magnesium and Cardiovascular Disease: A Review with Emphasis in Epidemiological Studies. Nutrients 2018, 10, 168.
- Champagne, C. Magnesium in Hypertension, Cardiovascular Disease, Metabolic Syndrome, and Other Conditions: A Review. Nutr. Clin. Pract. 2008, 23, 142–151.
- Zemel, P.C.; Zemel, M.; Urberg, M.; Douglas, F.L.; Geiser, R.; Sowers, J.R. Metabolic and hemodynamic effects of magnesium supplementation in patients with essential hypertension. Am. J. Clin. Nutr. 1990, 51, 665–669.
- Michoń, P. Level of total and ionized magnesium fraction based on biochemical analysis of blood and hair and effect of supplemented magnesium (Slow Mag B6) on selected parameters in hypertension of patients treated with various groups of drugs. Ann. Acad. Med. Stetin. 2002, 48, 85–97.
- Sebeková, K.; Revúsová, V.; Polakovicová, D.; Drahosová, J.; Zverková, D.; Dzúrik, R. Anti-hypertensive treatment with magnesium-aspartate-dichloride and its influence on peripheral serotonin metabolism in man: A subacute study. Cor et Vasa 1992, 34, 390–401.
- Shafique, M.; Misbah ul, A.; Ashraf, M. Role of magnesium in the management of hypertension. J. Pak. Med. Assoc. 1993, 43, 77–78.
- Motoyama, T.; Sano, H.; Fukuzaki, H. Oral magnesium supplementation in patients with essential hypertension. Hypertension 1989, 13, 227–232.
- Cohen, L.; Laor, A.; Kitzes, R. Reversible retinal vasospasm in magnesium-treated hypertension despite no significant change in blood pressure. Magnesium 1984, 3, 159–163.
- Haga, H. Effects of Dietary Magnesium Supplementation on Diurnal Variations of Blood Pressure and Plasma Na+, K+-ATPase Activity in Essential Hypertension. Jpn. Heart J. 1992, 33, 785–800.
- Turlapaty, P.; Altura, B. Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease. Science 1980, 208, 198–200.
- Kolte, D.; Vijayaraghavan, K.; Khera, S.; Sica, D.A.; Frishman, W.H. Role of Magnesium in Cardiovascular Diseases. Cardiol. Rev. 2014, 22, 182–192.
- Touyz, R.M. Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: Implications in hypertension. Am. J. Physiol. Circ. Physiol. 2008, 294, H1103–H1118.
- Kass, L.; Sullivan, K.R. Low Dietary Magnesium Intake and Hypertension. World J. Cardiovasc. Dis. 2016, 6, 447–457.
- Institute of Medicine (US) Food Forum. Providing Healthy and Safe Foods as We Age; The National Academies Press: Washington, DC, USA, 2010. Available online: https://pubmed.ncbi.nlm.nih.gov/21391340/ (accessed on 15 May 2020).
- Blumberg, J.B.; Frei, B.; Fulgoni, V.L.; Weaver, C.; Zeisel, S.H. Contribution of Dietary Supplements to Nutritional Adequacy in Various Adult Age Groups. Nutrients 2017, 9, 1325.
- Rosanoff, A.; Weaver, C.M.; Rude, R.K. Suboptimal magnesium status in the United States: Are the health consequences underestimated? Nutr. Rev. 2012, 70, 153–164.
- US Department of Agriculture; US Department of Health and Human Services. Dietary Guidelines for Americans, 2015–2020, 8th ed. Available online: https://health.gov/dietaryguidelines/2015/resources/2015-2020_Dietary_Guidelines.pdf (accessed on 7 March 2018).
- Greenland, P. Cardiovascular Guideline Skepticism vs Lifestyle Realism? JAMA 2018, 319, 117.
- Dominguez, L.J.; Veronese, N.; Barbagallo, M. Magnesium and Hypertension in Old Age. Nutrients 2020, 13, 139.